N/A
Completed N=22
Medication Adherence Given Individual SystemCHANGE(TM) in Advancing Nephropathy (MAGICIAN) Pilot Study
Chronic Kidney Disease(CKD)
Source: ClinicalTrials.gov NCT04616612 ↗
Enrolled (actual)
22
Serious AEs
0.0%
Results posted
Apr 2025
Primary outcomePrimary: Percentage of Daily Doses of Medication Taken as Prescribed (Medication Adherence) — 98; 74 percentage of Daily doses — p=.04
Summary
The purpose of this 2-group, randomized, controlled trial is to evaluate the refined SystemCHANGE™ against attention control patient education in CKD patients taking RAAS medications.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Daily Doses of Medication Taken as Prescribed (Medication Adherence) |
91; 59 | .04 sig |
| SECONDARY Number of Participants Qualitatively Analyzed From the Investigator-designed 10-item Acceptability Questionnaire Which Assesses Nurse-intervention Interaction and Mobile Technology Acceptability. |
6; 8 | — |
| SECONDARY Outcome Expectancy Questionnaire |
26.83; 24.57 | 0.11 |
| SECONDARY Credibility Questionnaire |
26.67; 25.89 | 0.66 |
| SECONDARY Personal Systems Thinking |
64.11; 76.17 | 0.84 |
Eligibility Criteria
Inclusion Criteria
- age > 18 years
- prescribed at least 1 daily RAAS inhibiting medication
- CKD diagnosis estimated glomerular filtration rate (eGFR) category G1 to G4
- RAAS inhibiting medication adherence of 150 mg/g or urine Albumin-to-Creatinine ratio >30mg/g
- able to speak, hear, and understand English determined by the ability to participate and comprehend conversation about potential inclusion in the study
- self-reported ability to open a pill cap
- able to self-administer RAAS inhibiting medications
- willing to use a study phone
- has no cognitive impairment as determined by a score of 4 or greater on the 6-item Telephone Mental Status Screen Derived from the Mini-Mental Status Exam (cognitive screener)
- has no other diagnoses that may shorten life span, such as metastatic cancer
- is not currently hospitalized
- receives care through two approved health care systems
Exclusion Criteria
- Participants with kidney failure defined by GFR <15 mL/min/1.73
- Participants will be excluded if they are receiving dialysis or have dialysis access placed (e.g. graft or arteriovenous fistula) in anticipation of starting dialysis.
- Kidney and kidney-pancreas transplant recipients will be excluded.
Data sourced from ClinicalTrials.gov (NCT04616612). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.